The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2016 | Why children should be offered choices in their treatment plans
Imelda Coyne, PhD from Trinity College Dublin, Dublin, Ireland discusses the value in involving children and adolescents in the decisions to be made beyond their treatment plan at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain. By providing children with choices such as which arm to insert their cannula in, how they would prefer their medicine to be administered or when they wish to receive treatment, allows them to feel more engaged and in control. The idea of offering children choices has not always been accepted but Prof. Coyne is an advocate of this concept.
